This follows AstraZeneca’s and Boehringer Ingelheim’s announcements to also cap their asthma chronic obstructive pulmonary disease drugs at $35.
GSK is the latest company to cap out-of-pocket costs at $35 monthly. for its asthma and chronic obstructive pulmonary disease (COPD) medicines. This program will be implemented no later than Jan. 1, 2025, the company said in the press release.
The medications included are:
GSK also recently reduced the wholesale acquisition cost for Advair Diskus by an average of 50% and Advair HFA by an average of 20%.
Related: AstraZeneca to Cap Asthma and COPD Meds at $35 a Month
Related: Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35
This follows AstraZeneca’s and Boehringer Ingelheim’s announcements to cap their respiratory medications at $35.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More